Pharma Equity Group Cash Flow Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-24.42	-24.35	-9.44
Depreciation & Amortization	0.24	0.22	0.54
Stock-Based Compensation	-	-	0.22
Other Operating Activities	1.32	-0.29	-0.37
Change in Accounts Receivable	1.87	-1.36	0.16
Change in Accounts Payable	-1.09	2.02	0.86
Change in Other Net Operating Assets	-0.77	2.73	-0.26
Operating Cash Flow	-22.86	-16.62	-8.3
Capital Expenditures	-	-0.07	-
Investing Cash Flow	-	-0.07	-
Short-Term Debt Issued	13.1	5.25	-
Long-Term Debt Issued	11.02	8	-
Total Debt Issued	24.11	13.25	-
Short-Term Debt Repaid	-32.32	-4.33	-
Long-Term Debt Repaid	-11.87	-0.2	-0.28
Total Debt Repaid	-44.19	-4.53	-0.28
Net Debt Issued (Repaid)	-20.07	8.72	-0.28
Issuance of Common Stock	51.15	12.19	-
Other Financing Activities	-8.21	-3.85	-
Financing Cash Flow	22.86	17.06	-0.28
Miscellaneous Cash Flow Adjustments	-	1.04	-
Net Cash Flow	0	1.4	-8.57
Free Cash Flow	-22.86	-16.7	-8.3
Free Cash Flow Per Share	-0.02	-0.01	-0.01
Cash Interest Paid	4.07	1.43	0.02
Cash Income Tax Paid	-2.23	-1.86	-1.48
Levered Free Cash Flow	-20.77	-65.07	-
Unlevered Free Cash Flow	-17.67	-64.1	-
Change in Net Working Capital	4.6	48.6	-

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.